Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network Read more about Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network4 views
Respiratory syncytial virus transmission in closed community settings that include children: a systematic review and meta-analysis Read more about Respiratory syncytial virus transmission in closed community settings that include children: a systematic review and meta-analysis4 views
ATAGI Targeted Review 2024: immunisation strategies for prevention and control of respiratory syncytial virus disease in Australia Read more about ATAGI Targeted Review 2024: immunisation strategies for prevention and control of respiratory syncytial virus disease in Australia6 views
Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia Read more about Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia14 views
Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS) Read more about Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS)8 views
A population-representative serosurvey estimating vaccine-induced immunity against measles, rubella, hepatitis B and severe acute respiratory syndrome coronavirus 2 in Timor-Leste Read more about A population-representative serosurvey estimating vaccine-induced immunity against measles, rubella, hepatitis B and severe acute respiratory syndrome coronavirus 2 in Timor-Leste23 views
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia Read more about Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia13 views
Nirsevimab: alleviating the burden of RSV morbidity in young children Read more about Nirsevimab: alleviating the burden of RSV morbidity in young children43 views
Nirsevimab: alleviating the burden of RSV morbidity in young children Read more about Nirsevimab: alleviating the burden of RSV morbidity in young children53 views
Clinical, genomic, and immunological characterization of RSV surge in Sydney, Australia, 2022 Read more about Clinical, genomic, and immunological characterization of RSV surge in Sydney, Australia, 202237 views
